Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

albumin human, USP · Albutein

Plasma-derived product · developed by Grifols Biologicals LLC

Approved FDA, Aug 1978

GRFS Developer

1 Registered trials

What is albumin human, USP?

Albumin human, USP (Albutein 20%) is a plasma-derived human albumin preparation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Albutein
Drug type: Plasma-derived product
Therapy area: Gastroenterology
Developer: Grifols Biologicals LLC (GRFS)
FDA status: Approved as Albutein (August 15, 1978), BLA102478

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03451292	Phase 3	Decompensated Cirrhosis and Ascites	Completed	GRFS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Decompensated Cirrhosis and Ascites

More from Grifols Biologicals LLC

Antithrombin III FDA approved factor VIII / von Willebrand factor FDA approved Alpha-1 Phase 3 C19-IG Phase 3 Fibrin Sealant Grifols Phase 3 GRF312 Phase 2 Human Plasma-Derived Fibrinogen Concentrate Phase 1/2 IVIG-PEG Phase 3 plasma-derived FVIII/VWF concentrate Phase 4

Sources

FDA Purple Book

Updated Oct 11, 2026. Something wrong or missing? Report it on the GRFS page.

Follow GRFS, the company behind albumin human, USP

See GRFS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GRFS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z